Four stocks from Barron's Better Bets (BBB) list currently provide 'safer' dividends with yields from $1,000 invested that exceed their share prices, fitting the 'dogcatcher' ideal. Analyst forecasts suggest these top-ten BBB Dogs could achieve an average net gain of 15.46% by August 2027, with 23% less risk than the market. However, five BBB stocks show negative free cash flow margins, making their dividends unsafe, so investors should focus on those with positive cash flow and yield parity. Market changes like corrections, dividend increases, or stock splits could increase the number of BBB Dogs priced fairly, offering better yield opportunities for contrarian investors.
Pfizer is currently seen as significantly undervalued despite uncertainties from patent expirations and declining COVID revenues. The company maintains strong profitability with free cash flow margins expected above 30% through the decade, supporting...
Pfizer, Chevron, and AbbVie have delivered strong dividend returns in 2026 and are positioned for further growth in 2027. Pfizer aims for $35 per share driven by obesity and oncology products, Chevron targets $250 supported by Guyana projects and AI ...
Hedge funds have been steadily buying Pfizer shares, attracted by its 6.3% dividend yield and promising oncology drug pipeline. Despite challenges from upcoming patent expirations that could impact earnings, Pfizer's late-stage cancer treatments and ...
In 2026, Merck's stock surged 44% year-to-date, outperforming major U.S. drugmakers Amgen (up 35%) and Pfizer (up 14%). Merck's success is driven by its strong oncology portfolio, including the top-selling cancer drug KEYTRUDA, and diverse products b...
Fairholme Capital, led by Bruce Berkowitz, holds 76.43% of its portfolio in St. Joe Company, a Northwest Florida land developer, reflecting strong conviction as the company posted its highest Q2 revenue in 20 years with significant margin expansions....
